Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorders now. Amyloid ß-protein (Aß) has been recognized as the leading cause of AD, and Aß oligomer plays an important role in the early stage of AD. Anti-Ab immunotherapy targeting on the Ab peptide has been demonstrated as one promising AD treatment. The active immunization, exploiting Ab42 as an immunogen, was initiated on AD animal model by Schenk in 1999 and then advanced to clinical trials. However, the clinical trial was haunted due to an occurrence of subacute meningoencephalitis in 6% of patients. Th1-biased responses stimulated by T cell epitope in the Ab42 and Th1-promoting adjuvant (QS-21) were ascribed to this side effect. Meanwhile, anti-Ab antibodies produced in those patients have been proved to be effective in slowering rate of cognitive decline. As an alternative, passive immunization approaches have the advantage of safety and efficacy over active immunization approaches. In this report, several strains of monoclonal antibody (MAb) against Aß1-42 oligomer or different truncation of Aß C terminal was established for AD therapeutic research. MAb specific for Aß1-42 oligomer was prepared with the hybridoma technique and purified through protein A affinity chromatography. The specificity, affinity and titers of the MAb were analyzed by ELISA, western blot and immunohistochemistry (IHC). To determine whether Antibodies treatment improves the ability of learning and memory, 8-month-old SAMP8 mice and 6-month-old APPswe/PS1DE9 mice were administered intraperitoneally and weekly with 400 mg A8 or nonspecific mouse IgG (Sigma-Aldrich) for 8 weeks. The Morris water maze (MWM) has been used for studying therapy-related changes in learning and memory in mice. The visible, hidden versions of MWM and prob trial were performed. The latency and distance to find the location that had contained the platform was measured. Data were recorded through an overhead camera linked with the computer to quantification of latency and distance. Mice were tested in a blinded manner, with group balanced for genotype and treatment. Mice were sacrificed 3 days after the final MWM manipulation for biochemical and histological assessment. Through western blot (WB) and immunohistochemistry (IHC), the soluble and insoluble Aß, phosphorylation of tau at 181/231/404 site, mTOR (mammalian target of rapamycin), LC3-I/II (microtubuler associated protein 1 light chain 3, MAP1rLC3, LC3), glial fibrillary acidic protein (GFAP), tubulin and actin were detected. Our results showed that the mice serum titer reached over 1:256,000 after immunization. Two hybridoma cell lines (BJ08 and BJNa) secreting MAb specific for the Aß1-42 oligomer was established after sub-cloning. They displayed much higher affinity to low molecular Aß1-42 oligomer, and showed the ability to bind Aß1-42 oligomer in the brain section of SAMP8 mice and APPswe/PS1DE9 mice. Using them as immunotherapy, we show that learning and memory ability was improved through intraperitoneal administration in SAMP8 mice. The mice that found the platform increased in antibody treated groups and our data showed a significant decrease in latency and distance compared with other groups (P < 0.05) (nonspecific mouse IgG, antibody solution buffer and no-treated SAMP8 or APPswe/PS1DE9 mice). Meanwhile, soluble Aß, phosphorylation of tau and LC3-II has also been inhibited after immunotherapy. In addition, the expression level of mTOR, GFAP, tubulin and actin were also detected with IHC and displayed no differences among these groups. In conclusion, the MAbs specific for Aß1-42 oligomer is developed. Therapeutic monoclonal antibodies against Aß oligomers have the efficacy in reducing soluble Aß, phosphorylation of tau and LC3-II level and ultimately ameliorated the learning and memory ability, which paves the way for further diagnostic and therapeutic research on AD.

Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease.

1H-MRS Assessment of the Therapeutic Effect of Bilateral Intraventricular BDNF Infusion into APP/PS1 Double Transgenic Mice

TrkB Agonistic Antibodies Superior to BDNF: Utility in Treating Motoneuron Degeneration

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage

Actions of the TrkB Agonist Antibody ZEB85 in Regulating the Architecture and Synaptic Plasticity in Hippocampal Neurons

Effect of Brain-Derived Neurotrophic Factor on Tyrosine Kinase B and Endogenous Brain-Derived Neurotrophic Factor Expressions by Lateral Ventricle Infusion into AD Mice

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Retracted: 1H-MRS Can Monitor Metabolites Changes of Lateral Intraventricular BDNF Infusion into a Mouse Model of Alzheimer’s Disease in Vivo [neuroscience 245 (2013) 40–49]

Therapeutic Potential of a TrkB Agonistic Antibody for Ischemic Brain Injury

1H-MRS can monitor metabolites changes of lateral intraventricular BDNF infusion into a mouse model of Alzheimer's disease in vivo.

The Prodrug of 7,8-Dihydroxyflavone Development and Therapeutic Efficacy for Treating Alzheimer's Disease.

A Small TAT-TrkB Peptide Prevents BDNF Receptor Cleavage and Restores Synaptic Physiology in Alzheimer's Disease

Multivalent Targeting of Blood-Brain Barrier LRP1 for Neurovascular Recovery Therapy for Alzheimer s Disease

Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice.

A Tetravalent TREM2 Agonistic Antibody Reduced Amyloid Pathology in a Mouse Model of Alzheimer's Disease.

Therapeutic Monoclonal Antibodies Against Abeta Oligomers for Treatment of Alzheimer's Disease

Therapeutic effects of anti-amyloid β antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer’s disease mouse model

Biomimetic Dendrimer–Peptide Conjugates for Early Multi‐Target Therapy of Alzheimer's Disease by Inflammatory Microenvironment Modulation

Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease

The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease